Roche (RHHBY) announced that the FDA accepted its Biologics License Application (BLA) seeking approval of OCREVUS (ocrelizumab) for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis under Priority Review. Its action date is December 28. The European Medicines Agency (EMA) validates its Marketing Authorization Application (MAA) for both indications. If approved, OCREVUS will be the first and only treatment indicated for both forms of MS (95% of MS cases).